Edwina Bartholomew has made a shock confession about her unique living situation with husband Neil Varcoe following her ...

Myeloid Therapeutics, a company developing in vivo cell therapies for cancer as well as a novel gene editing technology, has ...

The FDA previously granted breakthrough therapy designation to ziftomenib for relapsed/refractory NPM1-mutant AML.

A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...

Panelists discuss how chronic myeloid leukemia (CML) treatment has evolved over the past 5 years, highlighting advancements in tyrosine kinase inhibitor (TKI) therapy, improved adverse effect ...

Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros’ Proprietary OncotoX-AML Clinical Program ...

A new study has unveiled when chronic myeloid leukaemia, a type of cancer that affects the blood and bone marrow, arises in ...

A new study has unveiled when chronic myeloid leukemia, a type of cancer that affects the blood and bone marrow, arises in ...

Discover the latest findings on transplantation outcomes in Myelodysplastic Syndrome and Acute Myeloid Leukaemia from EBMT ...

Discover how maintenance therapy improves transplant outcomes for high-risk AML patients, with key insights from EBMT 2025.

CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ ...

Zhu and colleagues show that a subpopulation of spleen-derived fibroblasts secrete Gremlin 1, which suppresses chronic myeloid leukemia progression by inducing leukemia stem cell apoptosis through ...